H.C. Wainwright Reiterates Buy Rating on Janux Therapeutics (JANX)

April 22, 2026 6:42 AM

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $45.00 price target on Janux Therapeutics (NASDAQ: JANX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found